EV-MIME

Extracellular Vesicles (EVs) are produced from HEK293T cells that highly express NFAT3 transcription factor that inhibits cancer cell mobility and are loaded with a combination of miRNAs inhibiting tumor growth and cell mobility. In vitro evaluation revealed that these EVs significantly (80%) decrease invasive capacity of triple negative breast (MDA-MB-231, SUM-59PT) and pancreatic (BXPC3, MIA-PACA-2) cancer cell lines. These results were confirmed in vivo in a triplenegative breast cancer mouse model.

Applications

• Adjuvant therapy for triple negative breast cancer or pancreatic cancer as a single agent or in combination with other drugs
• Neoadjuvant therapy for triple negative breast cancer or pancreatic cancer as a single agent or in combination with other drugs

Competitive advantages

Mostly, the potential competitors’ approaches are at the early stage (proof of concept (PoC) to preclinical stages) and absence of available data does not allow direct comparison with this product.

Intellectual property

Two patent applications: WO2017167788A1 and WO2022136226A1

Keywords

Extracellular Vesicles - NFAT3 - miRNA - Triple negative breast cancer - Pancreatic cancer